Clinical Trials Browser

Phase 2 × Osteosarcoma × trastuzumab deruxtecan × Clear all

NCT04616560 2026-03-19

Trastuzumab Deruxtecan for the Treatment of HER2+ Newly Diagnosed or Recurrent Osteosarcoma

Phase 2 Suspended

Osteosarcoma